Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On January 23, 2026, Lisata Therapeutics, Inc. (the “Company”) and Qilu Pharmaceutical Co., Ltd. (“Qilu”) entered into a Mutual Termination Agreem